Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CardioSeal Septal Occluder

Known as: CardioSeal Septal Occluders, Septal Occluders, CardioSeal, Septal Occluder, CardioSeal 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Septal Occluder Device

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale.
AIMS Percutaneous patent foramen ovale (PFO) closure for secondary stroke prevention is discussed controversially. Long-term data… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Comparison of three patent foramen ovale closure devices in a randomized trial (Amplatzer versus CardioSEAL-STARflex versus Helex occluder).
This randomized trial compared procedural complications and 30-day clinical outcomes of 3 patent foramen ovale (PFO) closure… Expand
Is this relevant?
2008
2008
Late presentation of CardioSEAL PFO closure device fracture and thrombus formation three years after device implantation.
Transcatheter closure of patent foramen ovale (PFO) is a promising alternative to surgical closure or anticoagulation therapy in… Expand
Is this relevant?
2005
2005
CardioSEAL®, CardioSEAL-STARFlex®, and PFO-Star® Closure of PFO
Post utero, persistence of the patent foramen ovale (PFO) carries mischievous potential, as it appears to have no physiologic or… Expand
  • figure 1
Is this relevant?
2004
2004
CardioSEAL/STARflex versus Amplatzer devices for percutaneous closure of small to moderate (up to 18 mm) atrial septal defects.
Abstract Background The Amplatzer septal occluder (ASO) allows the percutaneous closure of small to very large atrial septal… Expand
Is this relevant?
2004
2004
Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism Periprocedural safety and mid-term follow-up results of three different device occluder systems
Aims Interventional PFO closure has previously been reported to reduce the risk for recurrent thromboembolic events. The aim of… Expand
Is this relevant?
2004
2004
CardioSEAL/STARflex versus Amplatzer devices for percutaneous closure of small to moderate (up to 18 mm) atrial septal defects.
BACKGROUND The Amplatzer septal occluder (ASO) allows the percutaneous closure of small to very large atrial septal defects (ASDs… Expand
Is this relevant?
2002
2002
[Interventional occlusion of foramen ovale and atrial septal defects after paradoxical embolism incidents].
Two hundred and fifty-one patients with a persistent foramen ovale (PFO), mean age 43.3 +/- 12.4 years, underwent catheter… Expand
Is this relevant?
2001
2001
Catheter closure of atrial septal defects and patent foramen ovale in patients with an atrial septal aneurysm using different devices.
BACKGROUND Atrial septal aneurysm is frequently associated with patent foramen ovale (PFO) and atrial septal defects (ASD… Expand
Is this relevant?
2001
2001
Patent foramen ovale closure in patients with transient ischemia attack/stroke.
Paradoxical embolism through a patent foramen ovale (PFO) has been recognized as a potential cause of transient ischemia attack… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE